OpGen, Inc. (OPGN) News
Filter OPGN News Items
OPGN News Results
|Loading, please wait...|
OPGN News Highlights
- For OPGN, its 30 day story count is now at 3.
- Over the past 1 day, the trend for OPGN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about OPGN are SAFE and TUEM.
Latest OPGN News From Around the Web
Below are the latest news stories about Opgen Inc that investors may wish to consider to help them evaluate OPGN as an investment opportunity.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Tuesday Morning The Trade: Tuesday Morning Corporation (NASDAQ: TUEM) COO Marc Katz acquired a total of 1884104 shares at
OpGen Announces Data from Prospective Randomized Controlled Multicenter Clinical Study Using the Unyvero HPN Panel for Hospitalized Patients with Suspicion of Pneumonia
- Unyvero reduced the use of inappropriate antibiotic therapy by 45.1%
Good morning, trader!
Thinking about buying stock in Travere Therapeutics, ADMA Biologics, Surgalign, CTI BioPharma, or OpGen?
NEW YORK , Aug. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TVTX, ADMA, SRGA, CTIC, and OPGN. Full story available on Benzinga.com
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of 0.00% and -22.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Total Revenue for Q2 2021 was approximately $0.8 millionCash as of June 30, 2021 was approximately $31.2 million, up significantly from the $13.4 million at year-end 2020 Conference call to be held at 4:30 p.m. Eastern Daylight Savings Time today ROCKVILLE, Md., Aug. 12, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today its financial and oper
ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that it has determined to withdraw from stockholder consideration Proposal 2 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on April 26, 2021, relating to an increase in the number of shares of capital stock
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OpGen to Provide Business Update and Financial Results for the Second Quarter 2021 on August 12th at 4:30 p.m. Eastern Time
ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2021 financial results after the close of the U.S. financial markets on Thursday, August 12, 2021. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities. Conference Ca
- OpGen subsidiary Curetis and its instrument development partner have completed assembly of 10 final pre-series release A30 RQ analyzers - Unyvero A30 RQ instruments are now readily available for final verification and validation testing ROCKVILLE, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that its subsidiary Curetis G